Lipe & Dalton Gilead Sciences, Inc. Transaction History

Lipe & Dalton

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 30, 2020	SELL	$62.1 - $78.08 $2.69 Million - $3.38 Million	-43,335 Closed	0 $0
Q2 2020 Aug 07, 2020	SELL	$72.34 - $84.0 $300,211 - $348,600	-4,150 Reduced 8.74%	43,335 $3.33 Million
Q1 2020 May 01, 2020	SELL	$62.63 - $80.22 $291,229 - $373,023	-4,650 Reduced 8.92%	47,485 $3.55 Million
Q4 2019 Jan 21, 2020	SELL	$61.62 - $67.78 $153,248 - $168,568	-2,487 Reduced 4.55%	52,135 $3.39 Million
Q3 2019 Nov 07, 2019	SELL	$62.51 - $69.0 $129,958 - $143,451	-2,079 Reduced 3.67%	54,622 $3.46 Million
Q2 2019 Jul 24, 2019	SELL	$61.87 - $69.38 $3,279 - $3,677	-53 Reduced 0.09%	56,701 $3.83 Million
Q1 2019 Apr 30, 2019	SELL	$62.53 - $70.05 $48,398 - $54,218	-774 Reduced 1.35%	56,754 $3.69 Million
Q4 2018 Feb 08, 2019	SELL	$60.54 - $79.0 $332,909 - $434,421	-5,499 Reduced 8.72%	57,528 $3.6 Million
Q3 2018 Nov 05, 2018	BUY	$71.28 - $78.92 $106,991 - $118,458	1,501 Added 2.44%	63,027 $4.87 Million
Q2 2018 Aug 06, 2018	BUY	$64.88 - $75.68 $711,474 - $829,906	10,966 Added 21.69%	61,526 $4.36 Million
Q1 2018 May 04, 2018	BUY	$72.84 - $88.8 $82,673 - $100,788	1,135 Added 2.3%	50,560 $3.81 Million
Q4 2017 Feb 13, 2018	SELL	$71.15 - $83.52 $78,620 - $92,289	-1,105 Reduced 2.19%	49,425 $3.54 Million
Q3 2017 Nov 03, 2017	BUY	$72.11 - $85.47 $24,517 - $29,059	340 Added 0.68%	50,530 $4.09 Million
Q2 2017 Aug 08, 2017	BUY	N/A	50,190	50,190 $3.55 Million

1,926

992M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Lipe & Dalton, based on Form 13F filings with the SEC.

Stay updated on Lipe & Dalton with notifications on news.